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Neutralizing antibody formation against transgene products can represent a major compli-
cation following gene therapy with treatment of genetic diseases, such as hemophilia
A. Although successful approaches have been developed to prevent the formation of
anti-factor VIII (FVIII) antibodies, innovative strategies to overcome pre-existing anti-FVIII
immune responses in FVIII-primed subjects are still lacking. Anti-FVIII neutralizing anti-
bodies circulate for long periods in part due to persistence of memory B-cells. Anti-CD20
targets a variety of B-cells (pre-B-cells to mature/memory cells); therefore, we investigated
the impact of B-cell depletion on anti-FVIII immune responses in hemophilia A mice using
anti-CD20 combined with regulatory T (Treg) cell expansion using IL-2/IL-2mAb complexes
plus rapamycin. We found that anti-CD20 alone can partially modulate anti-FVIII immune
responses in both unprimed and FVIII-primed hemophilia A mice. Moreover, in mice treated
with anti-CD20+IL-2/IL-2mAb complexes+rapamycin+FVIII, anti-FVIII antibody titers were
significantly reduced in comparison to mice treated with regimens targeting only B or T
cells. In addition, titers remained low after a second challenge with FVIII plasmid. Treg
cells and activation markers were transiently and significantly increased in the groups
treated with IL-2/IL-2mAb complexes; however, significant B-cell depletion was obtained
in anti-CD20-treated groups. Importantly, both FVIII-specific antibody-secreting cells and
memory B-cells were significantly reduced in mice treated with combination therapy. This
study demonstrates that a combination regimen is highly promising as a treatment option
for modulating anti-FVIII antibodies and facilitating induction of long-term tolerance to FVIII
in hemophilia A mice.
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INTRODUCTION
Hemophilia A is an X-linked, congenital bleeding disorder result-
ing from a deficiency of factor VIII (FVIII). Approximately 35%
of patients with hemophilia A develop complications of anti-
FVIII neutralizing antibodies following FVIII protein replace-
ment therapy (1, 2). In order to overcome anti-FVIII immune
responses, we sought transient immunosuppressive strategies that
can reduce pre-existing antibodies and induce long-term tolerance
to FVIII. CD20 is a 35-kDa transmembrane protein expressed
on B-cells from the pre-B-cell stage to mature B lymphocytes,
but not plasma cells (3). Monoclonal antibodies (mAbs) against
human CD20 (Rituximab) induce rapid B-cell depletion (4)
and is currently approved by the Food and Drug Administra-
tion (FDA) for treatment of non-Hodgkin B-cell lymphomas (5,
6) and several autoimmune disorders including type 1 diabetes
(T1D) (7), rheumatoid arthritis (8), and Sjögren’s syndrome (SS)
(9). Anti-CD20 depletes B-cells via several mechanisms (10, 11),
such as direct induction of apoptosis, antibody-dependent cell-
mediated cytotoxicity (ADCC) (12), and complement-dependent
lysis (CDC) (13), which are considered to be immediate and com-
paratively short-acting. Nevertheless, the clinical response to a
single course of the anti-CD20 mAb can be late acting and pro-
longed. This has led to the suggestion that anti-CD20 could also
have an immunization effect (14); however, it is unknown whether
this correlates with clinical outcome. Recently anti-CD20 IgG1
(15) and IgG2a (16) molecules have been used successfully to
prevent the production of anti-FVIII antibodies.
Webster et al. (17) defined a strategy in which complexes of
IL-2/IL-2-specific mAbs (JES6-1A12) can be used to selectively
expand CD4+CD25+Foxp3+ regulatory T (Treg) cells in vivo
with little or no change in other cell populations. This approach
has been used to successfully treat asthma (18) and experimen-
tal myasthenia gravis (MG) (19) in mouse models. In addition,
rapamycin is currently used as an immunosuppressive agent to
prevent acute graft rejection in humans (20). Rapamycin com-
bines with the intracellular immunophilin FK506-binding protein
(FKBP12) to form FKBP12-rapamycin complexes that inhibit the
activity of mammalian target of rapamycin (mTOR) and result
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in inhibiting effector T-cell (Teff) proliferation (21). Rapamycin
not only increased Treg:Teff cell ratios but also improved the
suppressive activity of Treg cells (22, 23).
In our previous studies, administration of IL-2/IL-2mAb com-
plexes prevented anti-FVIII immune responses in hemophilia A
mice following gene or protein replacement therapy (24, 25). Nev-
ertheless, overcoming pre-existing antibody responses in primed
subjects remains challenging. Anti-FVIII neutralizing antibodies
persist in part due to memory B-cells (26). Moreover, molec-
ular studies have shown that long-lived plasma cells (LLPCs)
can support chronic inflammatory processes by secreting path-
ogenic antibodies for long periods (27, 28). It is hypothesized
that LLPCs may also play an important role in prolonged pro-
duction of anti-FVIII antibodies in hemophilia A patients. In this
study, we developed a treatment strategy of single or combina-
tion therapy using agents targeting B-cells (to eliminate memory
responses) and those inducing Treg cell expansion (to suppress T
helper cell function). By using a combination of anti-CD20+IL-
2/IL-2mAb complexes+rapamycin, anti-FVIII immune responses
were significantly reduced. Hemophilia A mice treated with com-
bination therapy showed little or no anti-FVIII antibodies titers,
and this was also evident after a second challenge with FVIII plas-
mid. This study sought to identify strategies toward induction of
immune tolerance to FVIII transgene product following gene ther-
apy and to demonstrate that combination therapy targeting B and
T lymphocytes can be a viable option.
RESULTS
ANTI-CD20 TREATMENT CAN REGULATE ANTI-FVIII PRODUCTION IN A
NON-VIRAL GENE THERAPY MODEL
To test if B-cell depletion can regulate anti-FVIII immune
responses, we utilized anti-CD20 IgG2a antibody (anti-CD20)
in a murine model. Hemophilia A mice were divided into
two treatment groups (Figure 1 and Figure S1 in Supplemen-
tary Material): FVIII plasmid-treated mice were given anti-
CD20 (250µg/mouse) on days 0 and 14 combined with a
FVIII plasmid (pBS-HCRHPI-FVIIIA; 50µg/mouse) expressing
B domain-deleted hFVIII under the control of the liver-specific
hAAT promoter (HP) and the hepatic control region (HCR) on
day 0. Control mice were treated with rat IgG2a (250µg/mouse)
on days 0 and 14. Anti-CD20 significantly reduced total
B220+/CD19+ B-cells (80–90% reduction) both in blood (Figures
S1A,B in Supplementary Material) and spleen (Figure S1C in
Supplementary Material). B-cell depletion was sustained over 4–
6 weeks with gradual return to normal levels at 8 weeks following
treatment. No reduction in B-cell levels were observed in IgG2a
isotype-treated control and naive mice.
In order to investigate the best treatment schedule and thera-
peutic effects of anti-CD20 treatment, three groups of hemophilia
A mice were injected with three different dosages: 100µg/mouse
(on days −2, 0, 3, 6, and 9), 250µg/mouse (on days 0 and 14),
and 500µg/mouse (on day 0). Control mice were treated with
rat IgG2a 250µg/mouse on days 0 and 14. All mice were injected
with FVIII plasmid (50µg/mouse) at day 0. Following treatment,
FVIII activities and neutralizing antibody titers were assessed by
aPTT and Bethesda assays at different time points. In the rat IgG2a
control group, anti-FVIII antibody appeared within 2 weeks post
plasmid injection, increased to high-titers at 3–4 weeks, and main-
tained high-titer levels through 24 weeks. In addition, initially
high levels of FVIII activity decreased to low-undetectable levels
within 4 weeks (Figure 1). In the anti-CD20-treated groups, one
mouse from each group of mice had persistent FVIII activity with-
out detectable inhibitory anti-FVIII antibodies (Figure 1). The
remaining mice displayed delayed immune responses; however, all
mice generated moderate to high-titers of neutralizing antibodies
with FVIII activity decreasing to undetectable levels at 6–15 weeks.
While antibody titers were clearly reduced following anti-CD20
treatment, these titers increased over time. Although mice treated
with anti-CD20 were not completely resistant to FVIII immune
responses, they all exhibited partial modulatory effects compared
to the rat IgG2a treated control mice.
A similar treatment was given to FVIII plasmid-primed hemo-
philia A mice with pre-existing neutralizing antibodies. These
mice were developed by hydrodynamic injection of 50µg of FVIII
FIGURE 1 | FactorVIII gene expression and anti-FVIII antibody formation
after FVIII plasmid+anti-CD20 treatment in hemophilia A mice. Four
groups of hemophilia A mice were treated with FVIII plasmid (50µg/
treatment/mouse) at day 0 and i.v. injection of anti-CD20 at various doses and
schedules as listed in the following: group 1: 100µg/treatment/mouse,
injected at days −2, 0, 3, 6, and 9. Group 2: 250µg/treatment/mouse,
injected at days 0 and 14. Group 3: 500µg/treatment/mouse, injected at day
0. Group 4: control rat IgG, 250µg/treatment/mouse, injected at days 0 and
14. Peripheral blood samples were collected at different time points to
examine FVIII activities (A) and inhibitor titers (B). Each symbol represents
data obtained from an individual mouse. Data shown is representative of two
independent experiments.
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plasmid via tail vein, and only mice with neutralizing antibody
titers >30 Bethesda units (BU) were used. Mice were then treated
with anti-CD20 (n= 5; 250µg/mouse) on days −7, −4, and 0.
Control mice were treated with IgG2a (n= 2; 250µg/mouse) on
days−7,−4, and 0. Plasma samples were collected on day 1 follow-
ing treatment. As shown in Figure 2, neutralizing antibody titers
were maintained at high levels in rat IgG2a control-treated mice.
In contrast, neutralizing antibody titers were significantly reduced
following anti-CD20 treatment in 80% (four of five) treated
mice. In particular, 20% (one of five) of anti-CD20-treated mice
showed therapeutic FVIII activities levels for 14 weeks (Figure 2B).
These results indicate that anti-CD20 can partially modulate anti-
FVIII immune responses both in the FVIII unprimed and primed
hemophilia A mice.
COMBINATION TREATMENT WITH IL-2/IL-2mAb COMPLEXES,
RAPAMYCIN, AND ANTI-CD20 ENHANCED FVIII PLASMID-MEDIATED
GENE THERAPY IN HEMOPHILIA A MICE
Since anti-CD20 treatment can partially modulate anti-FVIII
immune responses in hemophilia A mice, we investigated whether
a combination therapy using anti-CD20 to deplete B-cells and
IL-2/IL-2mAb complexes to expand Treg cells (24) can more
consistently reduce anti-FVIII responses. Hemophilia A mice
were treated with: IL-2/IL-2mAb complexes+rapamycin+anti-
CD20+FVIII (n= 4, group 1; Figure 3A); IL-2/IL-2mAb
complexes+anti-CD20+FVIII (n= 4, group 2; Figure 3B);
IL-2/IL-2mAb complexes+rapamycin+FVIII (n= 3, group 3;
Figure 3C); anti-CD20+FVIII (n= 4, group 4; Figure 3D); and
mock agents (control inhibitor mice; n= 2, group 5; Figure 3E)
weekly for 4 weeks. FVIII protein (1 U/mouse) was given weekly
for 4 weeks for induction of FVIII-specific tolerance during the
treatment period. FVIII plasmid second challenge was applied at
5 weeks following 4 weeks of treatment (week 9). Except for con-
trol mice, all treated groups showed decreased antibody titers. The
most significant and prolonged reduction of neutralizing antibody
titers was observed using the combination treatment of IL-2/IL-
2mAb complexes+anti-CD20+rapamycin+FVIII (Figure 3A).
Neutralizing antibody titers were reduced to 0 in 50% (two of
four) treated mice, and a reversion of 8% FVIII gene expres-
sion was observed. Additional animals (n= 3–5/group) have been
treated in repeated experiments with similar results to those
shown (Figures 3A–E). In addition, treated mice were chal-
lenged with non-specific antigen, TNP-ficoll (24), at 16 weeks
following treatment (week 20). These animals responded simi-
larly to control/naive mice, demonstrating the tolerance effect was
FVIII-antigen-specific.
EFFECTS ON T/B-CELL RESPONSES IN PERIPHERAL BLOOD AND
SPLEEN WERE SIGNIFICANT IN TREATED HEMOPHILIA A MICE
Next, we evaluated changes in T- and B-cell popula-
tions of hemophilia A mice following treatment. We ana-
lyzed peripheral blood in mice treated with IL-2/IL-2mAb
complexes+rapamycin+anti-CD20+FVIII (n= 4). Mice with
neutralizing antibodies and those treated with anti-CD20+FVIII;
IL-2/IL-2mAb complexes+rapamycin+FVIII; and IL-2/IL-2mAb
complexes+anti-CD20+FVIII were used as control groups. Mice
were treated weekly with the indicated regimen for 4 weeks. Flow
cytometry analysis showed that the CD4+ T cells in total T-cell
populations did not significantly change over time (Figure 4A).
Interestingly, there was a slight decrease in the percentage and
numbers of CD4+ T cells in anti-CD20 treated groups. However,
the percentage of CD4+CD25+Foxp3+ T cells within the CD4+ T-
cell compartment was significantly increased in the IL-2/IL-2mAb
complexes treated groups compared to other groups for 4 weeks
during treatment period (Figure 4B; P < 0.05). The expanded
Treg cells declined rapidly to baseline levels within 2 weeks post
treatment. Similar to our previous studies (24, 25), IL-2/IL-2mAb
complex-expanded Treg cells showed considerably higher expres-
sion of molecules crucial for the suppressive function of Treg cells,
including CD25, glucocorticoid-induced tumor necrosis factor
receptor (GITR), and cytotoxic T-lymphocyte antigen 4 (CTLA-
4) (Figure 4C). The substantial increase in Treg cells following
injection of IL-2/IL-2mAb complexes occurred not only in blood
but also appeared as a fivefold increase in spleen (Figure S2A in
FIGURE 2 | FactorVIII gene expression and anti-FVIII antibody
titers following anti-CD20 treatment in FVIII plasmid-primed
hemophilia A mice with pre-existing inhibitors. Mice were primed
with FVIII plasmid to induce high-titer inhibitory antibodies at 8 weeks
before anti-CD20 treatment. The inhibitor mice were then treated with
anti-CD20. Group 1: control rat IgG, 250µg/treatment/mouse, injected
at days −7, −4, and 0. Group 2: anti-CD20, 250µg/treatment/mouse,
injected at days −7, −4, and 0. Peripheral blood samples were
collected at different time points to evaluate FVIII activities (A) and
inhibitor titers (B). Each symbol represents data obtained from an
individual mouse. Data shown is representative of two independent
experiments.
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FIGURE 3 | Immunomodulation with separate or combined therapy by
IL-2/IL-2mAb complexes, rapamycin, and anti-CD20 in FVIII
plasmid-primed hemophilia A mice with pre-existing inhibitors. Four
groups of hemophilia A inhibitor mice were treated separately with different
combined regimens: (A) IL-2/IL-2mAb complexes+rapamycin+
anti-CD20+FVIII injection (n=4, group 1), (B) IL-2/IL-2mAb
complexes+anti-CD20+FVIII (n=4, group 2), (C) IL-2/IL-2mAb
complexes+rapamycin+FVIII injection (n= 3, group 3), (D) anti-CD20+FVIII
injection (n= 4, group 4), and (E) Control inhibitor mice (n=2, group 5).
Each experimental group was treated with indicated immunomodulation
regimen weekly for 4 weeks. Anti-FVIII antibody titers were assessed by
Bethesda assay over time. Each symbol represents data obtained from an
individual mouse. Data shown is representative of three independent
experiments.
Supplementary Material; middle panel and Figure S2B in Supple-
mentary Material; upper panel). Almost all expanded Treg cells
were Helios+ (Figure S2A in Supplementary Material; right panel
and Figure S2B in Supplementary Material; upper panel) nat-
ural Treg cells derived from thymus. In contrast, no significant
change in the CD4+ T-cell population was observed in the spleen
(Figure S2A in Supplementary Material; left panel and Figure S2B
in Supplementary Material; upper panel). The expression levels of
the activation markers of Treg cells including CD25, GITR, and
CTLA-4 after IL-2/IL-2mAb complex treatment also reached high
levels in the spleen (Figure S2B in Supplementary Material; lower
panel).
Effects of anti-CD20 treatment were also evaluated on B-cell
populations in the hemophilia A mice treated with combination
therapy. After two treatments of anti-CD20, proportions of B-
cell populations were measured by flow cytometry. We observed
a significant decrease in proportions in the anti-CD20-treated
mouse groups of total B-cells (B220+ cells) (Figure 5A and Figure
S2C in Supplementary Material); mature B-cells (IgD+IgMlow)
(Figure 5B and Figure S2C in Supplementary Material); transi-
tional B-cells (IgM+IgDlow) (Figure 5C and Figure S2C in Sup-
plementary Material); memory B-cells (IgM−IgD−) (Figure S2C
in Supplementary Material); and plasma B-cells (B220−CD138+)
(Figure 5D).
COMBINATION THERAPY DEPLETES ANTI-FVIII-SPECIFIC
ANTIBODY-SECRETING CELLS (ASCS) AND FVIII-SPECIFIC MEMORY
B-CELLS IN MICE
Hemophilia A mice were treated with IL-2/IL-2mAb complexes+
rapamycin+anti-CD20+FVIII; IL-2/IL-2mAb complexes+
rapamycin+FVIII; anti-CD20+FVIII; and FVIII alone as
described previously. CD138+ cells were obtained from spleens
of treated mice 2 weeks following treatment. Plasma cells were
incubated with FVIII and analyzed for the formation of spots
in an ELISPOT assay. Anti-FVIII ASCs correlated with the
number of cells plated. Total anti-FVIII ASCs were reduced in
mice treated with IL-2/IL-2mAb complexes+rapamycin+anti-
CD20+FVIII and IL-2/IL-2mAb complexes+rapamycin+FVIII
compared to other groups (Figure 6A). To confirm specificity
of the assay, naive mice that had not been treated with FVIII
were included. No FVIII-specific ASCs were detected in these
mice (Figure 6A). Furthermore, no background staining in
plates without FVIII immobilization was observed using cells
obtained from FVIII-treated mice (data not shown). Evaluation of
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FIGURE 4 | Effects of immunomodulation on CD4+ T cells,
CD4+CD25+Foxp3+ Treg cells andTregs activation markers in peripheral
blood of treated hemophilia A inhibitor mice over time. Lymphocytes
were isolated from the blood of naive (light grid), inhibitor only (light slant),
anti-CD20+FVIII (white), IL-2/IL-2mAb complexes+rapamycin+FVIII (light
gray), IL-2/IL-2mAb complexes+anti-CD20+FVIII (dark gray), and IL-2/IL-2mAb
complexes+rapamycin+anti-CD20+FVIII (black) treated mice. (A) CD4+ in
total T cells and (B) CD4+CD25+Foxp3+ in CD4+ T cells were stained and
analyzed by flow cytometry during the treatment. (C) Blood cells were also
stained and analyzed for Treg cells markers: CD25, GITR, and CTLA-4. Data
shown are median fluorescence intensity (MFI) values of the three activation
markers. Data shown is representative of two independent experiments.
FVIII-specific ASCs and memory B-cells at later time points (4 and
6 weeks) after treatment showed similar results as those obtained
at 2 weeks.
We also assessed whether depletion of FVIII-specific memory
B-cells occurred following treatment. We isolated CD138−
spleen cells (presumably containing FVIII-specific memory B-
cells) from hemophilia A mice treated with different sin-
gle or combined regimens and re-stimulated these cells
with high-dose FVIII (2 U/well). FVIII-specific memory B-
cells were detected by ELISPOT. Interestingly, FVIII-specific
memory B-cells were significantly reduced only in the IL-
2/IL-2mAb complexes+rapamycin+anti-CD20+FVIII and anti-
CD20+FVIII-treated mouse groups (Figure 6B).
DISCUSSION
Treatment of hemophilia A patients with inhibitors is very
challenging and costly. In addition, probability of morbidity is
increased in these patients. Although treatments with inhibitors
has been successful in hemophilia mice, it is very challenging to
decrease pre-existing anti-FVIII neutralizing antibodies in FVIII-
primed hemophilia A mice. In vivo expansion of activated Tregs
had profound suppressive effects and was able to prevent forma-
tion of anti-FVIII antibodies in both gene therapy and protein
replacement therapy treated mice; however, this regimen can only
transiently modulate pre-existing anti-FVIII immune responses.
Anti-FVIII neutralizing antibodies can circulate for long periods
and is thought to be partly due to the persistence of memory
B and plasma cells. In a preliminary experiment, we found that
either use of bortezomib (an inhibitor of 26S proteasome that
can reduce/eliminate plasma cells) alone or in combination with
T-cell-regulating agents such as IL-2/IL-2mAb complexes did not
help reduce pre-existing neutralizing antibody titers (data not
shown). Meslier et al. (29) reported similar results that borte-
zomib only delayed the onset of FVIII neutralizing antibodies
in hemophilia A mice but failed to eliminate established anti-
FVIII IgG-producing cells. Anti-CD20 mAbs can deplete pan B
lymphocytes, from pre-B-cells to memory B-cells, ranging from
50 to 90%. Rituximab (anti-human CD20) is beneficial in treat-
ing patients with acquired hemophilia (30). Limited data have
also been described in case reports with respect to the use of
Rituximab in children (31, 32) and adults (31, 33) with con-
genital hemophilia A and neutralizing antibodies. It has been
hypothesized that concurrent administration of anti-CD20 and
high-dose FVIII might be beneficial to treat hemophilia A patients
with neutralizing antibodies. Emerging data suggests that repop-
ulating transitional murine and human B-cells (which increase
markedly in numbers following anti-CD20 depletion therapy)
exhibited potent regulatory activity (34). Therefore, use of anti-
CD20 may promote effects distinct from merely reducing the
mature B-cell pool. IL-10 expressing immature B-cells may pro-
mote a regulatory environment to aid in tolerance induction
(35, 36). As anti-CD20 treatment exhibits a distinct mechanism
of action and relatively few side effects, it is an excellent can-
didate agent for combinational approaches. Thus, we set out
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FIGURE 5 | Effects of immunomodulation on total B, mature B,
transitional B, and plasma B-cells in peripheral blood of each mouse
group. Lymphocytes were isolated from the blood of naive (light grid),
Inhibitor only (light slant), anti-CD20+FVIII (white), IL-2/IL-2mAb
complexes+rapamycin+FVIII (light gray) IL-2/IL-2mAb
complexes+anti-CD20+FVIII (dark gray), and IL-2/IL-2mAb
complexes+rapamycin+anti-CD20+FVIII (black) treated mice. (A) B220+
B-cells, (B) IgM+IgDhi B-cells, (C) transitional B-cells, and (D) plasma cells
were stained and analyzed by flow cytometry during the treatment period
(week 2, 4, and 5). Data shown are cell percentages (A–C) and real numbers
(D) of the B-cell populations. Data shown is representative of two
independent experiments.
FIGURE 6 | Depletion of FVIII-specific ASCs (Antibody-Secreting Cells)
and memory B-cells in the inhibitor mice treated with IL-2/IL-2mAb
complexes plus rapamycin and anti-CD20. Cells were isolated by MACS
from spleens of naive (light slant), FVIII plasmid only (white),
anti-CD20+FVIII (light gray), IL-2/IL-2mAb complexes+rapamycin+FVIII
(dark gray), and IL-2/IL-2mAb complexes+rapamycin+anti-CD20+FVIII
(black) treated mice (n=2, each group) 2 weeks after treatment.
(A) 3×106 cells were used to detect FVIII-specific ASC cells by ELISPOT
assay. (B) 5×105 non-plasma cells were cultured and stimulated with FVIII
at 10 U/ml for 6-days, and memory B-cells were detected by ELISPOT
assay. Data shown are mean of spot numbers for each treated group
(n=2).
to study whether anti-CD20 treatment alone or in combina-
tion with other immune tolerance therapies can be more ben-
eficial to treat hemophilia subjects with pre-existing inhibitory
antibodies.
With anti-CD20 treatment alone, we found that anti-FVIII neu-
tralizing antibody titers were reduced in both FVIII unprimed
and primed hemophilia A mice. However, antibodies were not
completely eliminated and FVIII activity did not improve in these
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animals. To further improve the therapeutic efficacy, we com-
bined B-cell depletion using anti-CD20 with in vivo Treg cell
expansion using IL-2/IL-2mAb complexes+rapamycin to treat
hemophilia A inhibitor mice. Our previous studies using IL-2/IL-
2mAb complexes alone showed five to sevenfold expansion of
highly suppressive Treg cells in vivo, which induced long-term
tolerance to FVIII in unprimed hemophilia A mice following
gene therapy (24). IL-2/IL-2mAb complexes that can selectively
promote human Treg expansion are currently under develop-
ment. Although no clinical trials have been initiated so far, IL-
2/IL-2mAb complexes have high potential as a clinically feasible
strategy; however, IL-2/IL-2mAb complex single treatment in the
hemophilia A “inhibitor” mice only transiently reduced neutral-
izing antibody titers during treatment. It has been shown that
rapamycin blocked T-cell-cycle progression from G1 to S phase
after activation (37) and promoted TCR-induced T-cell anergy
(38), achieving induction of operational tolerance (39). Addi-
tionally, rapamycin enriched antigen-specific Foxp3+ Treg cells to
promote organ transplant tolerance (40) and inhibited relapsing
experimental autoimmune encephalomyelitis (EAE) by modula-
tion of both effector/regulatory T cells (41). Moghimi et al. (42)
reported that transient oral delivery of rapamycin combined with
repeated injections of low doses of FVIII prevented induction of
neutralizing antibody responses in hemophilia A mice. Thus, we
adopted a treatment strategy that included rapamycin with IL-
2/IL-2mAb complexes to enhance Treg cell function in vivo for
targeting T-cell-mediated immune responses and induction of
FVIII-specific tolerance in hemophilia A mice with pre-existing
antibodies.
Our results demonstrate that treatment with IL-2/IL-2mAb
complexes+rapamycin had a synergistic effect when combined
with anti-CD20 antibody to reduce neutralizing antibody titers.
In contrast, mice treated with anti-CD20 only or different com-
binations only transiently reduced neutralizing antibody titers. In
our immunomodulation studies,we also included weekly injection
of FVIII protein (1 U/mouse/treatment) for induction of FVIII-
specific tolerance. Furthermore, no increase in neutralizing anti-
body titers was observed following a second FVIII plasmid chal-
lenge, indicating induction of tolerance to FVIII. The mechanistic
studies showed that the combined therapy promoted immune
tolerance by increasing CD4+CD25+Foxp3+ Treg cells and their
activation markers CD25, GITR, and CTLA-4. Furthermore, com-
bined treatment using anti-CD20 showed 98% depletion of total
B, mature B, transitional B, and plasma cells. Changes in T/B-cell
populations were not only detectable in the peripheral blood but
also found in splenocytes isolated from treated mice. Most impor-
tantly, FVIII-specific ASCs and memory B-cells were reduced fol-
lowing treatment with combination therapy. It was demonstrated
that anti-CD20 predominantly depleted FVIII-specific memory
B-cells, and IL-2/IL-2mAb complexes+rapamycin helped reduce
FVIII-specific ASCs. In Figure S2C in Supplementary Material, the
percentage of total memory T cells (gated as IgM−IgD− popula-
tion) increased due to the more significant depletion (98%) of
total B, mature B, and transitional B-cells. However, we found
that FVIII-specific memory B-cells were significantly reduced
after anti-CD20 treatment (shown in Figure 6B) in both mouse
groups treated with anti-CD20 combination regimen. Whether the
effects of IL-2/IL-2mAb complexes+rapamycin on B-cells were
attributed to impaired TH cell responses or directly mediated by
the immune complexes is unclear. Upon second challenge with
FVIII plasmid, the antibody titer remained low without an increase
in FVIII activity, indicating that only partial tolerance against FVIII
was achieved with combination therapy. Furthermore, treated
mice were challenged with non-specific antigen, TNP-ficoll (24) at
16 weeks following treatment and responded similarly to control
mice, demonstrating that this tolerance effect is FVIII-antigen-
specific. Based on these results, we hypothesize that residual,
long-lived FVIII-specific plasma cells may contribute to sustained
low-titer neutralizing antibodies that limit the therapeutic benefits
of immunomodulatory regimens.
Zhang et al. showed that a single dose of anti-CD20 IgG1 pre-
treatment prevented the increase of neutralizing antibodies in
hemophilia A mice receiving high-dose protein replacement ther-
apy (15). These antibodies can selectively deplete follicular B-cells
while sparing marginal zone (MZ) B-cells as potential tolerogenic
antigen-presenting cells. Interestingly, this treatment also led to
an increase of Treg cells. In a similar case, Sarikonda et al. showed
that transient B-cell depletion with anti-CD20 IgG2a in combi-
nation with proinsulin resulted in modest increases in Treg cells
and offered limited efficacy in type 1 diabetes (T1D) prevention in
NOD mice (7). In rhesus macaques, Mingozzi et al. (43) success-
fully used Rituximab in combination with cyclosporine to erad-
icate anti-human factor IX antibody following AAV8-mediated
gene therapy. In addition, transient B-cell depletion by anti-CD20
IgG2a prevented FVIII inhibitor formation in hemophilia A mice
receiving protein therapy but failed to induce long-term toler-
ance (16). In our study, administration of anti-murine CD20
IgG2a significantly reduced CD19+ B-cells in blood, spleen, and
lymph nodes, as well as neutralizing antibody titers in FVIII
plasmid-treated mice. Furthermore, our results showed that com-
bination therapy targeting both B and T cells had better results
to more significantly reduce anti-FVIII immune responses. As
shown in our previous experiments, FVIII expression persisted
in the liver for very long periods following hydrodynamic deliv-
ery of FVIII plasmids. With reversion of FVIII expression, FVIII
antigen is present continuously during follow-up. Thus, it is con-
cluded that long lasting FVIII-specific partial tolerance has been
achieved with the combination therapy. In addition, viral gene
transfer with adenoid-associated viral (AAV) vectors has been pro-
posed as a therapeutic strategy for hemophilia A (44, 45). The
immunomodulation regimens developed for transgene-specific
immune responses may also be helpful in the design of modu-
latory protocols for immune responses to gene transfer vectors,
in particular pre-existing immunity against viral vectors such as
AAV. In addition, liver-directed gene transfers with several vec-
tors have been associated with the induction of tolerance to the
expressed transgene (46, 47). Combination of the immunomod-
ulatory regimen developed in this study with liver gene transfer
should increase the efficacy of tolerization against FVIII trans-
gene. In summary, we demonstrated that IL-2/IL-2mAb complexes
plus rapamycin acted synergistically with anti-CD20 to promote
induction of immune tolerance to FVIII by increasing the num-
ber and function of CD4+CD25+Foxp3+ Treg cells as well as
eliminating both FVIII-specific ASCs and memory B-cells. These
findings provide important preclinical evidence for the safety
and enhanced therapeutic efficacy of the combined treatment
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for antibody responses in hemophilia A patients with pre-existing
inhibitors.
MATERIALS AND METHODS
MICE
All mice were kept according to the National Institutes of Health
guidelines for animal care and the guidelines of Seattle Children’s
Research Institute, and maintained at a specific pathogen-free
(SPF) facility. Hemophilia A mice in a 129/SV×C57BL/6 mixed
genetic background were generated by targeted disruption of exon
16 of FVIII gene (48) and were used at the age of 6–8 weeks.
IMMUNOMODULATION USING IL-2/IL-2mAb COMPLEXES IN
HEMOPHILIA A MICE TREATING WITH FVIII PLASMID
Hemophilia A mice were intravenously (i.v.) injected with 50µg
of FVIII plasmid [pBS-HCRHPI-FVIIIA (49)] in 2 ml phosphate-
buffered saline (PBS) via tail vein in 8–10 s. IL-2/IL-2mAb com-
plexes were prepared as previously described (17). One microgram
recombinant mouse IL-2 (PeproTech, Rocky Hill, NJ, USA) was
mixed with 5µg anti-IL-2mAb (JES6-1A12) (eBioscience, San
Diego, CA, USA), incubated at 37°C for 30 min, and then injected
intraperitoneally (i.p.) into mice according to schedules specified
in Results. Groups of IL-2/IL-2mAb complexes only treated mice,
FVIII plasmid only treated mice, and naive mice were included as
controls. Selected mice treated with immunomodulation received
a second plasmid challenge at 9 weeks after the first treatment with
immunomodulation therapy. Blood samples were taken from the
retro-orbital plexus at serial time points and assessed for FVIII
activity and anti-FVIII antibody levels.
B-CELLS DEPLETION BY ANTI-CD20 TREATMENT
Mice were depleted of B-cells using anti-murine CD20 IgG2a anti-
body (clone 18B12; Biogen Idec, Weston, MA, USA) at indicated
schedules and dosages. To assess B-cell depletion, mice were given
two i.v. doses 14 days apart, and peripheral blood and spleen
tissues were collected at different time points after the first and
second doses. Peripheral blood was collected in microcapillary
tubes with 3.8% sodium citrate solution via retro-orbital plexus,
centrifuged to remove plasma, and remaining cells suspended in
PBS for staining and flow cytometry.
FLOW CYTOMETRY AND ANTIBODIES
Cell suspensions of peripheral blood, lymph nodes (LNs from
superficial cervical), and spleens of each treated mouse group were
prepared according to standard protocols. Cell suspensions were
stained for FACS analysis using the following antibodies (obtained
from eBioscience unless otherwise stated): PE-Cy5-anti-mouse
CD25; FITC-anti-mouse CD62L (L-selectin); Alexa Fluor®647-
anti-mouse/rat Foxp3; PE-anti-mouse CD152 (CTLA-4); Alexa
Fluor®700-anti-mouse CD4 (BD Pharmingen™; San Jose, CA,
USA); PE-Cy7-anti-mouse GITR (BD Pharmingen™); Alexa
Fluor®700-anti-mouse B220; FITC-anti-mouse IgD; PE-Cy7-anti-
mouse IgM and PE-anti-mouse CD138. Cells were first stained
for T-cell surface markers CD4, CD25, CD62L, and GITR, and
subsequently stained intracellularly with T-cell markers for Foxp3
and CTLA-4 following the company protocol (eBioscience). For
B-cell populations, cells were stained with surface markers B220,
IgD, IgM, and CD138. Samples were analyzed on an LSRII flow
cytometer (Becton Dickinson, Palo Alto, CA, USA) and data were
analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
FVIII ACTIVITIES AND INHIBITOR TITERS ASSAYS
Peripheral blood samples were taken from the experimental mice
and collected in a 3.8% sodium citrate solution. FVIII activities
were measured by a modified clotting assay using FVIII deficient
plasma and reagents to measure activated partial thromboplastin
time (APTT) and FVIII deficient plasma (49, 50). FVIII activities
were calculated from a standard curve generated by using serially
diluted normal human pooled plasma. Anti-FVIII activities were
measured by Bethesda assay as previously described (51).
ELISPOT ASSAY
In preparation for the enzyme-linked immunospot (ELISPOT)
assay, spleen cells from the treated mice were prepared to isolate
the CD138+ (ASCs plasma) cells, 96-well filter plates (Millipore,
MAHA N4510) were coated with the ASC cells (1× 106/well)
and incubated overnight at 4°C. To detect the ASC cells, plates
were washed and blocked with RPMI-1640 supplemented with
10% preselected fetal calf serum (Hyclone, Logan, Utah), 2 mM l-
glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin (all from
Life Technologies), and 5× 105 M β-mercaptoethanol (Sigma-
Aldrich) for 1 h at 37°C prior to detection. The restimulation of
memory B-cells in vitro was achieved as described. (26) Briefly,
spleen cells were isolated and depleted of CD138+ ASCs. CD138−
spleen cells were cultured at 3× 105 cells/well in RPMI-1640
medium at 37°C for 6-days. About 2 U/well of FVIII was added
to the cells on day 0. After 6-days culture, newly formed ASCs
were detected by ELISPOT assays.
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Figure S1 | B-cell depletion following anti-CD20 treatment in hemophilia A
mice. Mice were treated with i.v. injection of FVIII plasmid (50µg at day 0) and
anti-CD20 (gray) or IgG2a isotype control (white) at a dose of 250µg/injection at
days 0 and 14. PBMCs and spleen cells isolated from anti-CD20 treated
hemophilia A mice were stained with FITC-CD19, and APC-B220 at 0.5, 2, 4, 8,
12, and 16 weeks following plasmid treatment and analyzed by flow cytometry.
Naïve (black) and IgG control-treated hemophilia A mice were used as controls.
(A) Representative plot for blood cells at different time points, (B) Total B-cell
(CD19+B220+) depletion in blood over time, (C) Total B-cell (CD19+B220+)
depletion in spleen over time. Data shown is representative of two independent
experiments.
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Figure S2 | Effects of immunomodulation on bothT and B-cells isolated
from spleens of each treated mouse group. Spleen (A–C) cells were
collected and isolated at serial time points from naive (light slant), FVIII plasmid
only (white), anti-CD20+FVIII (light gray), IL-2/IL-2mAb
complexes+rapamycin+FVIII (dark gray), and IL-2/IL-2mAb
complexes+rapamycin+anti-CD20+FVIII (black) treated mice (n=2, each
group). Cells were stained and analyzed for T-cell populations (A,B) and B-cell
populations (C). Data shown is representative of two independent experiments.
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